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Nanoassembly routes stimulate 
conflicting antibody quantity and 
quality for transmission-blocking 
malaria vaccines
Darren B. Leneghan  1, Kazutoyo Miura2, Iona J. Taylor1, Yuanyuan Li1, Jing Jin1, Karl D. 
Brune  3, Martin F. Bachmann1,4, Mark Howarth3, Carole A. Long2 & Sumi Biswas1
Vaccine development efforts have recently focused on enabling strong immune responses to poorly 
immunogenic antigens, via display on multimerisation scaffolds or virus like particles (VLPs). Typically 
such studies demonstrate improved antibody titer comparing monomeric and nano-arrayed antigen. 
There are many such studies and scaffold technologies, but minimal side-by-side evaluation of 
platforms for both the amount and efficacy of antibodies induced. Here we present direct comparison 
of three leading platforms displaying the promising malaria transmission-blocking vaccine (TBV) target 
Pfs25. These platforms encompass the three important routes to antigen-scaffold linkage: genetic 
fusion, chemical cross-linking and plug-and-display SpyTag/SpyCatcher conjugation. We demonstrate 
that chemically-conjugated Qβ VLPs elicited the highest quantity of antibodies, while SpyCatcher-
AP205-VLPs elicited the highest quality anti-Pfs25 antibodies for transmission blocking upon mosquito 
feeding. These quantative and qualitative features will guide future nanoassembly optimisation, as well 
as the development of the new generation of malaria vaccines targeting transmission.
The development of effective vaccines is recognised as one of the greatest achievements in medicine1. Historically, 
most vaccines have been attenuated or inactivated formulations of whole-organisms given prophylactically. In 
the modern vaccination age, the pathway to licensure and deployment can be significantly more difficult for these 
types of complex whole-organism vaccine as they sometimes induce strong reactogenicity2 in vaccinees such 
as high fever, nausea and headache. This is particularly undesirable in low-income settings where symptoms of 
reactogenicity can be confused for symptoms of disease, straining already minimal healthcare resources. These 
factors have spurred a move in the focus of both academic research institutions and the pharmaceutical industry 
towards defined subunit-based vaccines.
Subunit vaccines typically comprise purified antigens or parts of antigens (sub-domains or peptides) that 
elicit a protective immune response3. The disadvantage of this approach to vaccination however, is that on their 
own subunit antigens are often not immunogenic enough to elicit a protective immune response4. For this reason 
subunit vaccines generally incorporate some form of immunostimulant. One such immunostimulant that has 
recently “come of age”5 is the use of self-assembling protein nanoparticles, commonly multimerisation domains 
or virus-like particles (VLPs) to display the antigen of interest. VLPs are made by recombinantly expressing coat, 
envelope or capsid viral proteins in a heterologous system and are able to self-assemble into particulate structures 
which take advantage of the key immunologic features of viruses such as repetitive surfaces and activation of 
pathogen-associated molecular pattern recognition receptors5. As well as being able to induce a strong response 
against the virus from which they are derived, VLPs can also be used to display foreign antigens by either genetic 
fusion to the coat protein or other means of conjugation. Display of foreign antigens to the immune system in this 
manner is able to elicit much stronger cellular and humoral immunity than soluble antigen alone6, 7.
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Transmission blocking malaria vaccines (TBVs) aim to inhibit sexual reproduction of the malaria parasite by 
eliciting antibodies which prevent the parasite from replicating within the mosquito vector. Antibodies generated 
by vaccination with the Plasmodium falciparum malaria transmission blocking antigen Pfs25 have been widely 
reported to be able to completely inhibit parasite development4, 8–11 making it an exciting TBV candidate. A suc-
cessful TBV would be an important supplement to traditional malaria control strategies in countries seeking to 
ease the burden of endemic malaria12. As TBVs rely solely on antibodies for their functional action13, TBVs are 
an excellent model to assess differences in functional efficacy elicited by different immunostimulant scaffolds.
Numerous studies have detailed novel VLPs14–19 and their immunogenic properties, however it is unclear 
whether every VLP is equally effective. There are several studies reporting that antigens conjugated to VLPs are 
significantly more immunogenic than soluble antigen alone6, 20 but side-by-side comparison of the same antigen 
on several VLP platforms has not been reported. Though some studies have compared VLPs to other scaffolds 
such as genetically detoxified diphtheria toxin21, spherical vs. rod shaped VLP assemblies22, as well as the adjuvant 
ability of various polysaccharide carriers23.
In this study we have compared three leading platforms displaying Pfs25. These platforms comprise the three 
important routes to antigen-scaffold linkage: genetic fusion, chemical cross-linking and plug-and-display SpyTag/
SpyCatcher. The first, IMX313, is a multimerisation domain based on a hybrid version of the chicken complement 
inhibitor C4b-binding protein (C4bp). Previous work has shown IMX313 fused to various antigens increases 
antibody titer and avidity as well as improving antigen localisation to lymph nodes and improving cellular immu-
nogenicity4, 24. The second, SpyCatcher-AP205, is a novel VLP strategy we recently established6, 25 which allows 
covalent conjugation of antigen to VLP by the formation of a spontaneous isopeptide bond between SpyCatcher 
and its partner SpyTag26. Fusion of SpyCatcher to the VLP and SpyTag to the antigen allows heterologous expres-
sion of antigen and VLP in the system most suited to each and avoids the typical downfalls of antigen-fusion 
VLPs such as poor expression levels, poor solubility and misfolding. This system has shown promising improve-
ments in antigen immunogenicity compared to monomeric antigen in adjuvant6. Finally, chemical crosslinking of 
antigen to VLPs consisting of the coat protein of the bacteriophage Qβ has been shown to improve immunogenic-
ity in disease areas such as influenza27, malaria28, and Alzheimer’s29, as well as nicotine addiction30 and diabetes31.
Herein we determine that there are key differences in the improved immunogenicity between the three immu-
nostimulant scaffolds. Further we demonstrate a discordance between the antibody titer induced by each plat-
form and the functional efficacy of those antibodies.
Results
Generation and biophysical analysis of nanoparticle vaccines. Pfs25-IMX313 and Pfs25-
SpyTag:SpyCatcher-AP205 were successfully expressed and purified as previously described (Fig. 1A and B)4, 6. 
Pfs25 coupled to Qβ by chemical crosslinking (Fig. 1C) was analysed by Coomassie-stained reducing (Fig. 1C) 
and non-reducing (Fig. S1) SDS-PAGE, as well as by Western blot using Pfs25-specific monoclonal antibodies 
(Fig. S1). Particle integrity was confirmed by size exclusion chromatography (Fig. 1C) and electron microscopy 
(Fig. 1C). Qβ coat protein migrated at the expected size of ~14 kDa in its reduced form. Addition of maleimide 
groups (derivatisation) induced a band pattern consistent with internally crosslinked multimers corresponding to 
2×, 3×, 4× Qβ (Fig. S1). The non-reduced forms of both pre- and post-derivatisation Qβ are consistent with the 
formation of higher order oligomers. Addition of sulfhydryl groups to Pfs25 did not appear to significantly change 
its migration pattern on SDS-PAGE, though recognition of the non-reduced form of thio-Pfs25 was recognised 
more strongly than the non-reduced form of untreated Pfs25 by both mAbs (4B7 and 32F81) suggesting addition 
of sulfhydryl groups may partially unfold the structure of the protein (Fig. S1). These mAbs have previously been 
described to detect the reduced and non-reduced forms of Pfs25 with different intensity32, 33. Successful crosslink-
ing of one Pfs25 molecule to one Qβ molecule should result in a monomer of approximately 32 kDa. A band of 
approximately the correct size (indicated by (iii)) is evident on the Coomassie-stained gel (Fig. 1 C2) as well as 
the Western blots (Fig. S1), indicating successful conjugation. Higher order conjugates are also evident (Fig. S1).
To determine the conjugation efficiency of Pfs25 to Qβ, the Coomassie-stained gel was analysed by densi-
tometry. By comparing the relative pixel intensity between the Qβ monomer and Qβ-Pfs25 and adjusting for the 
change in molecular weight, the efficiency of coupling was estimated to be between 7% and 11% for a number of 
different coupling experiments. Given that each Qβ particle is made up of 180 monomers34, this gives between 
13 and 20 Pfs25 monomers per particle. This is the minimum conjugation efficiency; evident higher order bands 
on both Western blot and Coomassie-stained gel mean that the true number of Pfs25 monomers per particle 
is in reality much higher but due to the indistinct nature of the bands it is impossible to accurately estimate by 
densitometry. The dose required for immunisation was calculated based on this minimum conjugation efficiency. 
So as not to unfairly bias towards Pfs25-Qβ, 25% of the calculated dose (3 μg of Pfs25-Qβ) was used; comparison 
by polyclonal stained Western blot of 1 µg of Pfs25-Qβ against 1 µg of Pfs25 (data not shown) was used as a guide 
for this estimate.
Electron microscopy of the VLP preparations revealed intact Pfs25-Qβ VLPs and Pfs25-SpyTag:SpyCatcher-AP205 
VLPs of approximately the expected size, ~35 nm (Fig. 1, B3 and C3). Size exclusion chromatography of Pfs25-Qβ 
and Pfs25-SpyTag:SpyCatcher-AP205 demonstrated elution profiles in the expected range for VLPs (Fig. 1, B3 and 
C3), while the elution profile for Pfs25-IMX313 is consistent with the size previously reported4.
Nanoparticle vaccines are strongly immunogenic. Groups of 10 mice were immunised with doses 
normalised to 1 μg Pfs25 antigen content and formulated in Alhydrogel (Table 1). Three weeks after the priming 
immunisation, mice in each of the groups, except those that had received monomeric Pfs25, showed detecta-
ble level of antibody responses (Fig. 2A). Following the boosting dose, each of the groups demonstrated some 
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Figure 1. Generation and characterisation of nanoparticles used in this study. (A) Pfs25-IMX313 (1). 
Schematic of construct design particle and formation illustrating monomer (i) and heptamer (ii). (2) SDS-
PAGE showing reduced monomer (i) and non-reduced heptamer (ii). (3) Size exclusion chromatography 
trace illustrating heptamer migration in the expected range. (B) Pfs25-SpyTag:SpyCatcher-AP205 (1) 
Schematic of construct design and particle formation illustrating SpyCatcher-AP205 (i), Pfs25-SpyTag (ii), 
and Pfs25-SpyTag:SpyCatcher-AP205 conjugate (iii). (2) Reducing SDS-PAGE showing SpyCatcher-AP205 
(i), Pfs25-SpyTag (ii), and Pfs25-SpyTag:SpyCatcher-AP205 conjugate (iii). (3) Negatively stained TEM of 
Pfs25-SpyTag:SpyCatcher-AP205, scale bar = 50 nm and size exclusion chromatography trace illustrating 
VLP migration in the expected range. (C) Pfs25-Qβ (1) Schematic of construct design and particle formation 
illustrating Qβ VLPs (i), Pfs25 (ii), and Pfs25-Qβ conjugate (iii). (2) Reducing SDS-PAGE showing Qβ VLPs (i), 
Pfs25 (ii), and Pfs25-Qβ conjugate (iii). (3) Negatively stained TEM of Pfs25-Qβ VLPs, scale bar = 50 nm and 
size exclusion chromatography trace illustrating VLP migration in the expected range. Numbers at the left of the 
coomassie images represent size in kDa. Size markers in all size exclusion traces are from left to right: 670, 158, 
75, 44, 29 and 13.7 kDa.
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response to Pfs25. The poorest response unsurprisingly came from the group of mice immunised with mono-
meric Pfs25 in Alhydrogel.
Of the groups that received nanoparticle vaccines, Pfs25-SpyTag:SpyCatcher-AP205 and Pfs25-Qβ had 
a significantly higher anti-Pfs25 antibody titer than those that received monomeric Pfs25 after the priming 
immunisation (Pfs25-SpyTag:SpyCatcher-AP205 p < 0.001, Pfs25- Qβ p < 0.0001). Subsequently all three nano-
particle groups had a significantly higher anti-Pfs25 antibody titer post boost (Pfs25-SpyTag:SpyCatcher-AP205 
p < 0.05, Pfs25-Qβ p < 0.0001, Pfs25-IMX313 p < 0.05). Comparing only within the groups that received the 
nanoparticle vaccines the Pfs25-Qβ group had significantly higher antibody response than Pfs25-IMX313 
post prime (p < 0.01) and significantly higher response than both Pfs25-IMX313 (p < 0.05) and 
Pfs25-SpyTag:SpyCatcher-AP205 (p < 0.05) post boost. There was no significant difference between the 
Pfs25-IMX313 and Pfs25-SpyTag:SpyCatcher-AP205 groups at any time point measured (p > 0.05, Fig. 2A).
Antibody avidity was measured using the chaotropic agent sodium thiocyanate (NaSCN) to displace serum 
antibodies in ELISA35. Using this method we determined for each the avidity EC50 (amount of NaSCN required 
to decrease OD in the ELISA by 50%). The mice that received Pfs25-Qβ generated an antibody response with 
significantly higher avidity than both the monomeric Pfs25 and Pfs25-IMX313 groups. The Pfs25-Qβ immu-
nised mice did not develop significantly higher avidity antibodies than the Pfs25-SpyTag:SpyCatcher-AP205 
(p > 0.05) group although there is a trend towards higher avidity. Both the Pfs25-Qβ (p < 0.001) and 
Pfs25-SpyTag:SpyCatcher-AP205 (p < 0.05) immunised groups generated a significantly higher avidity antibod-
ies than monomeric Pfs25 immunised mice (Fig. 2B).
Vaccine-induced antibodies recognise native Pfs25 antigen. Expression of Pfs25 occurs on the 
ookinete surface in the midgut of the mosquito vector8. Using P. berghei parasites transgenically expressing P. 
falciparum Pfs25 (Pfs25DR3), we assessed the ability of IgG induced by vaccination to recognise native antigen 
on the ookinete surface (Fig. 3). Pooled sera from each group recognised Pfs25 on the surface of the parasite in an 
identical pattern to the 4B7 positive control. Only weak staining was observed with the sera from mice vaccinated 
with monomeric Pfs25, likely due to the significantly lower immunogenicity of this vaccine, so this immunoflu-
orescence assay was performed at a lower serum dilution than the nanoparticle immunised sera. Serum from 
ovalbumin-immunised mice was used as a negative control.
Discordance between titer and functional efficacy of vaccine-induced antibody responses. The 
functional efficacy of the immune response generated by the different vaccines was determined by standard 
membrane feeding assay (SMFA). This assay involves feeding live mosquitoes with a mixture of P. falciparum 
malaria-infected blood and purified IgG from each group, with dissection in order to determine the number of 
oocysts which develop36. Functional efficacy is determined by a reduction in the number of oocysts compared 
to a negative control group lacking protective antibody, this is termed the transmission reducing activity (TRA). 
In the first feeding assay (Feed #1), all purified IgG from the pooled serum of each group was tested at a single 
concentration of 750 μg/ml (Table 2 and Fig. S2). This assay demonstrated that the anti-Pfs25 IgG induced by 
vaccination with each of the nanoparticles had functional transmission-reducing activity (TRA) (Table 2 and 
Fig. S2). Unsurprisingly the TRA of the anti-Pfs25 IgG induced by monomeric Pfs25 was significantly lower in 
this experiment (Table 2 and Fig. S2, p = 0.184). Therefore, in the following two feeds (Feed #2 and Feed #3), 
purified IgGs of the Pfs25-IMX313, Pfs25-Qβ and Pfs25-SpyTag:SpyCatcher-AP205 groups were evaluated at 
three-fold dilutions starting at 750 μg/ml (750, 250, 83.3 & 27.7 μg/ml), to dissect whether there was a qualitative 
difference in transmission reducing activity between the anti-Pfs25 IgG induced by the three nanoparticle vac-
cines (Table 2 and Fig. 4).
Combined analysis of Feeds #2 and #3 demonstrated that, Pfs25-SpyTag:SpyCatcher-AP205 had statistically 
lower oocysts (i.e., higher TRA, Holm adjusted p-values < 0.042) than either Pfs25-IMX313 or Pfs25-Qβ except 
at the 750 μg/ml dilution (p = 0.042 to Pfs25-IMX313, but p = 0.213 to Pfs25-Qβ) when tested at the same total 
IgG concentrations. At 83.3 and 250 μg/ml, Pfs25-Qβ showed significantly lower oocysts (p = 0.030 and 0.020, 
respectively) than Pfs25-IMX313 (Table 2 and Fig. 4).
Further dissection of the functional efficacy of the anti-Pfs25 IgG induced by each platform is facilitated by 
determining the relationship between anti-Pfs25 antibody titers in the purified IgG used and the SMFA results. 
In a multiple linear regression analysis, anti-Pfs25 and vaccine groups were used as explanatory variables to 
determine the “transmission blocking efficacy per anti-Pfs25 antibody unit” (Fig. 5A). The overall fit to the linear 
regression model was R2 = 0.72, and both anti-Pfs25 AU (p < 0.0001) and vaccine groups (p = 0.0018) showed 
significant effects. Among the three vaccines, the Pfs25-SpyTag:SpyCatcher-AP205 group showed significantly 
higher activity after adjusting AU (p = 0.0057 to Pfs25-IMX313, and p = 0.0016 to Pfs25-Qβ), but there was no 
significant difference between Pfs25-IMX313 and Pfs25-Qβ (p = 0.4754).
Antigen Produced in Dose: Pfs25 µg (total protein µg)
Pfs25 P. pastoris 1 (1)
Pfs25-IMX313 P. pastoris 1 (1.35)
Pfs25-Qβ P. pastoris and E. coli 1 (3)
Pfs25-SpyTag:SpyCatcher-AP205 HEK293E and E. coli 1 (2.24)
Table 1. Vaccine origin and dose details.
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We further determined “transmission reducing efficacy per volume (ml) of serum” using the dilution fac-
tor of the serum pool in a feeder (more specifically, reciprocal of dilution) as one of the explanatory varia-
bles, instead of anti-Pfs25 AU (Fig. 5B). In other words, we tried to evaluate how efficacious is each response 
in the undiluted mouse serum from each group (to assess the combined consequences of antibody quantity 
and quality). The overall fit to the linear regression model was R2 = 0.70, and both dilution factor (p < 0.0001) 
and vaccine groups (p = 0.0016) showed significant effects. When three groups were compared, Pfs25-Qβ and 
Pfs25-SpyTag:SpyCatcher-AP205 were able to induce a similarly efficacious response (p = 0.4512). Both of these 
vaccines were significantly better than Pfs25-IMX313 (Fig. 5B, p = 0.0094 and 0.0019, respectively). The similarity 
between Pfs25-Qβ and Pfs25-SpyTag:SpyCatcher-AP205 is due to the fact that, while Pfs25-Qβ induced a higher 
titer (Fig. 2A), the response was less efficacious per antibody unit (Fig. 5A).
Figure 2. Immunogenicity of nanoparticle vaccines. (A) Anti-Pfs25 IgG titers measured by ELISA in mice 
(n = 10) vaccinated twice with doses corresponding to 1 μg Pfs25 per immunisation in Alhydrogel® at three 
weeks post prime (left panel) and three weeks post boost (right panel). (B) Avidity of serum IgG responses was 
assessed by NaSCN-displacement ELISA and is reported as the reduction in OD by incubation with varying 
concentrations of NaSCN compared to incubation with PBS (left panel). Lines represent the arithmetic mean of 
the combined data from each mouse within the group. EC50 (concentration of NaSCN required to reduce the 
OD405 to 50% of that without NaSCN) was then determined using a sigmoidal dose response (variable slope) 
regression (right panel). ns p > 0.05, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.
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Discussion
In this study we have successfully generated and characterised Pfs25-Qβ VLPs (Fig. 1A). We further established 
that chemically crosslinking Pfs25 to VLPs of bacteriophage Qβ coat protein increases its immunogenicity sig-
nificantly (Fig. 2A), as well as generating significantly higher avidity antibodies (Fig. 2B). This is consistent with 
previous reports that crosslinking peptides/antigens to Qβ VLPs improves immunogenicity28–30 as well as with 
reports that the immunogenicity of Pfs25 is improved by conjugation to VLPs or protein nanoparticles4, 6, 9, 25.
Furthermore, we successfully replicated previous reports of immunogenicity enhancement using IMX313 and 
SpyCatcher-AP205 platforms4, 6, 25 (Fig. 2). Unsurprisingly monomeric Pfs25 was significantly less immunogenic 
than any of the protein-nanoparticle platforms studied (Fig. 2). Side-by-side comparison of the three platforms 
displaying Pfs25 revealed some differences in both the magnitude (Fig. 2A) of the immune response as well as the 
efficacy of that response (Figs 4 and 5). Qβ not only increased immunogenicity compared to monomeric Pfs25 
but ELISA titers were approximately a log higher than the titers at the corresponding time points from both other 
platforms (Fig. 2A). Similarly Qβ elicited a humoral response with significantly higher antibody avidity than 
Pfs25-IMX313 (Fig. 2B).
Functional efficacy measured by SMFA is the true readout of this study; SMFA is the gold standard for testing 
TBV candidates36. In SMFA, it is well appreciated that the error of assay is larger, especially when a weaker sample 
is tested in a single assay. It is true not only in our facility, but also in other laboratories37. Two main readouts 
are commonly given from SMFA: % inhibition in mean oocyst count (TRA) and % inhibition in prevalence 
(transmission blocking activity or TBA). However these readouts cannot be compared unless the mean number 
of oocysts in the controls are similar, and TBA is the function of TRA and mean control oocysts37. Therefore, 
we reported 95% CI for each % inhibition estimate (Table 2) and analysed data by combining multiple feeds at 
multiple concentrations (Fig. 4). Using this assay and combining the outcome with the antibody titers measured 
by ELISA we are able to determine the per-AU efficacy induced by each platform (Fig. 5A). We reproducibly 
demonstrated the antibodies induced by SpyCatcher-AP205 were able to block transmission much more strongly 
Figure 3. Binding of anti-Pfs25 IgG to native antigen. Ookinetes of P. berghei transgenic for Pfs25 (Pfs25DR3) 
were stained with 4B7 (positive control) or pooled post boost sera from mice immunised with one of the 
nanoparticle vaccines, monomeric Pfs25 or ovalbumin (OVA) (negative control). Antibody binding was 
detected by Alexa Fluor® 488-conjugated goat anti-mouse IgG (green) and the DNA was stained with DAPI 
(blue). Phase contrast as well as merged view are also shown. White bars correspond to 5 μm.
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than those elicited by either IMX313 or Qβ at the same anti-Pfs25 AU. Indeed these other two platforms nearly 
overlapped in their per-AU efficacy (Fig. 5A). This result indicates that the antibodies to Pfs25 in the mice immu-
nised with Pfs25-SpyTag:SpyCatcher-AP205 must be restricted to a more functionally relevant subset of epitopes, 
i.e. are more likely to block the Pfs25 function that is required for establishing infection in the mosquito midgut.
The cause of this effect is likely twofold: first chemical modification of Pfs25 to allow conjugation to Qβ at least 
partially unfolds the protein. The monoclonal antibody 4B7 has been demonstrated to bind to the reduced form 
of recombinant Pfs25 more strongly than to non-reduced Pfs254, implying that it binds to a reducible unfolded 
epitope. As we demonstrated by Western blot, (Fig. S1) 4B7 binds more strongly to the thiolated-Pfs25 than to 
unthiolated-Pfs25, strongly suggesting protein unfolding. This unfolded protein conjugated to the Qβ-VLP will 
likely stimulate generation of antibodies to these partially unfolded epitopes distracting the immune response 
from relevant functional ones. Secondly display on AP205 is ordered: each Pfs25 molecule is anchored in the 
same C-terminal manner similar to its predicted display on the native parasite surface. Native Pfs25 is anchored 
by a C-terminal GPI-anchor8 and this is mimicked by display on SpyCatcher-AP205. Display on Qβ is disor-
dered, essentially taking place between functionalised amine residues, meaning there are up to 25 possible con-
jugation sites on Pfs258, though it is possible that not all are surface exposed. As a result Pfs25 is potentially 
displayed on the surface of Qβ in one of up to 25 orientations. Though it is difficult to determine the exact antigen 
Sample Conca
Mean 
Oocb % inhibitionc p valued
Feed #1
4B7 93.75 0.5 98.4 (95, 99.5) <0.001
OVA 750 26.2 N/A N/A
Pfs25 750 12.7 51.6 (−35.3, 83.7) 0.184
Pfs25-IMX313 750 0 100 (99.3, 100) <0.001
Pfs25-Qβ 750 0.1 99.8 (98.7, 100) <0.001
Pfs25-SpyTag:SpyCatcher-AP205 750 0 100 (99.4, 100) <0.001
Feed #2
4B7 93.75 2.35 97.9 (93.9, 99.3) <0.001
OVA 750 75.85 N/A N/A
Pfs25-IMX313
750 1.2 98.4 (95.2, 99.5) <0.001
250 14.35 81.1 (45.3, 93.6) 0.004
83.3 47.75 37 (−74.8, 76.2) 0.406
27.8 56.8 25.1 (−123.3, 76.1) 0.598
Pfs25-Qβ
750 0.45 99.4 (98, 99.9) <0.001
250 8.85 88.3 (66.1, 96.1) <0.001
83.3 39.6 47.8 (−58, 82.1) 0.249
27.8 60.05 20.8 (−121.5, 72.3) 0.664
Pfs25-SpyTag: SpyCatcher-AP205
750 0 100 (99.7, 100) <0.001
250 0.15 99.8 (99.3,100) <0.001
83.3 5.4 92.9 (79.4, 97.6) <0.001
27.8 27.45 63.8 (−1, 87.4) 0.051
Feed #3
4B7 93.75 0.3 98.4 (95.2, 99.6) <0.001
OVA 750 16.1 N/A N/A
Pfs25-IMX313
750 0.05 99.7 (98.8, 100) <0.001
250 1.1 93.2 (77.3, 98.7) <0.001
83.3 7.05 56.2 (−33.1, 85.5) 0.152
27.8 5.75 64.3 (−11.5, 88.8) 0.07
Pfs25-Qβ
750 0 100 (98.8, 100) <0.001
250 0.25 98.4 (94.6, 100) <0.001
83.3 1.8 88.8 (63.7, 96.5) <0.001
27.8 6.65 58.7 (−30.2, 88.6) 0.131
Pfs25-SpyTag: SpyCatcher-AP205
750 0 100 (99, 100) <0.001
250 0 100 (99.3, 100) <0.001
83.3 0 100 (99, 100) <0.001
27.8 0.75 95.3 (83.1, 100) <0.001
Table 2. Transmission reducing activity of IgG from immunised mice. aIgG concentration (μg/ml) in feeder. 
bArithmetic mean of oocyst intensity from 20 mosquitoes. cPercent inhibition of mean oocyst intensity and the 
95% confidence interval (95% CI). dTwo-sided p values testing whether % inhibition is significantly different 
from zero.
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density on the surface of Qβ, the fact that some monomeric Qβ coat protein (~14 kDa, Fig. 1C and Fig. S1) 
is detectable by reducing Coomassie-stained SDS-PAGE indicates that the coupling density is less than 100%. 
Conversely 100% coupling, i.e. each coat protein molecule is linked to a Pfs25-SpyTag molecule, of Pfs25-SpyTag 
to SpyCatcher-AP205 is readily evident (Fig. 1B). The combination of these factors is likely to explain the differ-
ences in functional efficacy observed between Qβ and SpyCatcher-AP205.
The differences between SpyCatcher-AP205 and IMX313 are probably explained in a similar fashion. While 
Pfs25 is fused at its C-terminus to IMX313 the fact that there are only ~7 molecules of Pfs25 per nanoparticle 
means that functional epitopes are arrayed differently to those on SpyCatcher-AP205. Extrapolating from the 
structure of C4bp we expect Pfs25-IMX313 to form a heptagonal flat disc4, 38, 39, whereby Pfs25 is displayed at the 
vertices of the disc exposing functionally non-relevant epitopes on each molecule’s side.
When functional efficacy of each platform is related to the hypothetical serum dilution used in the SMFA, 
we again establish that SpyCatcher-AP205 induces the most functionally efficacious response, though the differ-
ences between SpyCatcher-AP205 and Qβ are not as striking in this analysis. This reinforces the contention that 
antibodies induced by SpyCatcher-AP205 are more functionally relevant for transmission blocking. Even though 
per-ml of serum there are fewer anti-Pfs25 antibodies; since the proportion of total anti-Pfs25 response that is 
functionally relevant is much higher, less serum is required to effectively block transmission.
Differences in the IgG subclass elicited by each platform are worth considering as a potential source of the 
differences in functional efficacy that we observe in this study. However, in contrast to anti-Pfs230 antibod-
ies, there is no report showing that anti-Pfs25 antibodies require complement to show functional efficacy in 
SMFA40–42. Indeed in this and previous studies to assess Pfs25 vaccine efficacy, we have performed the SMFA 
using heat-inactivated serum4, 6 thereby precluding a role for complement. Therefore, we deem it unlikely that 
IgG subclass profile has a significant impact on functional efficacy measured in the SMFA in the case of Pfs25 
vaccines.
To date four Pfs25 candidate vaccines have progressed to Phase Ia clinical trials (Pfs25-EPA conjugate, Pfs25 
VLP-FhCMB (Fraunhofer USA Center for Molecular Biotechnology), Chimpanzee Adenovirus 63 (ChAd63) 
Pfs25-IMX313/Modified vaccinia Ankara (MVA) Pfs25-IMX313, and Pfs25-Pfs25 conjugate; clinicaltrials.gov 
search term “Pfs25”) and there are a number of others in pre-clinical development4, 6, 9, 25. We have previously 
demonstrated an improvement in the functional quality of the antibody response elicited by vaccination with 
Pfs25-IMX313 over monomeric Pfs254. This study confirms that there is significant value in analysing not only 
Figure 4. Transmission blocking efficacy of anti-Pfs25 IgG induced by nanoparticle vaccines. Total IgG 
was purified from the pooled serum of each group (3 weeks post boost). The purified IgG was mixed with 
P. falciparum NF54 cultured gametocytes and fed to A. stephensi mosquitoes (n = 20 per test group) in two 
independent SMFA experiments. (A,B) IgG from ovalbumin-immunized mice was used as a negative control; 
the transmission blocking anti-Pfs25 mAb 4B7 was used as a positive control. Midguts were dissected 7 days 
post-feeding. Data points represent the number of oocysts in individual mosquitoes and the lines show the 
arithmetic mean (A,B). x-axis values are μg/ml total IgG in the assay.
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the immunogenicity and functional efficacy of a candidate vaccine but also the relationship between the two, and 
this should inform the design of future clinical trials.
Of the display technologies used in this study, to date only a Qβ VLP has been tested in clinical trials 
(NCT00369616 & NCT01280968), as an anti-nicotine immunotherapy. These studies were unable to detect a 
statistically significant difference in long-term smoking cessation between participants receiving vaccine and 
those receiving placebo43. Nicotine is a small molecule alkaloid and as such a conjugation to Qβ is unlikely to 
affect its structure, in contrast to a protein conjugate which has secondary and tertiary structure which can be dis-
rupted by chemical conjugation. No nicotine addiction vaccine trial has to date demonstrated an improvement in 
smoking cessation, Pfs25 vaccines have however demonstrated functional efficacy44, 45. The clinical results of the 
Qβ-nicotine VLP unfortunately therefore do not particularly inform its relevance to the field of protein-subunit 
vaccines: however the results of our study likely eliminate its selection as a candidate platform for a Pfs25 vaccine.
Of the other platforms tested in this study, IMX313 has completed one first-in-human phase 1 trial to evaluate 
the safety and immunogenicity of a candidate tuberculosis vaccine expressed via viral vectors rather than as a 
protein46. Pfs25-IMX313 is currently undergoing a phase Ia clinical trial in a ChAd63-MVA viral vectored formu-
lation (NCT02532049). We have previously demonstrated that in this formulation IMX313 does not significantly 
improve the quality of the vaccine-induced immune response but does increase its magnitude4; results of this trial 
are expected in early 2018. Conversely Pfs25-IMX313 does improve the quality of the vaccine induced immune 
response when delivered as a protein-in-adjuvant in pre-clinical studies4. Neither AP205 nor SpyCatcher have 
any available clinical data.
Taken together these results demonstrate that improving the number of antibodies to a vaccine antigen should 
not be the only consideration when selecting an antigen display technology such as a VLP or nanoparticle; the 
quality of the response induced by vaccination is of major importance. The importance of antibody quality has 
been shown previously for vaccines for other infectious diseases47–50, as well as during natural responses to infec-
tion51, 52. Platform technologies which improve antibody titer must therefore be carefully compared and consid-
ered in order to determine which will improve the candidate vaccine. If simply improving antibody titer to any 
part of the antigen is sufficient then Qβ may be the best platform. However if a focused response is required to the 
antigen in a specific orientation, then SpyCatcher-AP205 is a superior platform. The biochemistry underpinning 
SpyCatcher-SpyTag allows versatile antigen coupling orientation by changing the position of SpyTag, which can 
be placed at either terminus of a candidate antigen or even within surface exposed flexible loops53. This would 
allow orientation on the VLP surface to be specifically chosen to display the most functional epitopes.
Future work to determine whether this property is specific to SpyCatcher conjugation on the surface of bac-
teriophage VLPs or is a generalizable property of SpyCatcher-VLP fusions will be of value to the field of vac-
cinology. If it is indeed a generalizable property, it will be useful to demonstrate efficacy on as many VLPs as 
Figure 5. Comparison of the quality of the anti-Pfs25 IgG induced by nanoparticle vaccines. (A) The square 
root of anti-Pfs25 specific IgG level in the feeder is shown on the x-axis. The ratio of mean oocyst counts in 
control and test samples are plotted on a log scale along (log-mean ratio, LMR) the y-axis. (B) The reciprocal of 
the dilution factor from the original serum pool is plotted on the x-axis. LMR is plotted on the y-axis. When a 
test sample showed 100% inhibition in the SMFA, the LMR was assigned as 3.5 (dotted line) in the figures.
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possible in order to create a diverse library of potential scaffold technologies. A highly effective malaria vaccine 
is likely to incorporate elements targeting multiple stages of the parasite life-cycle, and transmission blocking 
vaccines will ultimately be a crucial component. A clear understanding of the quantity and quality of the immune 
response required for a TBV to be effective will be of great benefit to the field. Modular VLP technologies such as 
SpyCatcher-AP205 are a useful tool to help dissect that response and to bring an effective TBV closer to fruition.
Experimental Procedures
Expression and purification of proteins. Qβ VLPs were grown in JM109 E. coli cells containing the 
pQβ10 plasmid described previously54. A starter culture of 50 ml was grown overnight at 37 °C with shaking in 
lysogeny broth (LB) supplemented with 50 μg/ml carbenicillin. This culture was then inoculated into 450 ml of 
complete M9 media (11.28 g/L M9 minimal salts, 10 g/L acid-hydrolysed casein, 2 mM MgSO4, 1 g/L glucose, 
50 μg/ml carbenicillin) and incubated at 37 °C with shaking for a further 24 h. Cells were pelleted at 6000 × g 
for 15 min at 4 °C and frozen at −20 °C overnight to aid lysis. The cell pellet was then resuspended in 20 ml lysis 
buffer (20 mM Na2HPO4, 0.1% triton-X 100, 5 mM EDTA, 2 mg/ml lysozyme, pH 7.5) and incubated at room 
temperature for 20 min before addition of benzonase at a concentration 100 U/g of cell pellet with a further incu-
bation at room temperature for 20 min. This was then subjected to 5 cycles of freeze thaw in a dry ice/methanol 
bath. The cell debris were pelleted by centrifugation at 15,500 × g for 30 min at 4 °C and the resulting supernatant 
was filtered through 0.85, 0.45 and 0.22 μm filters in succession. This was mixed with an equal volume of 100% 
(NH4)2SO4 and incubated on ice for 1 h to precipitate the VLPs. Precipitated VLPs were pelleted by centrifugation 
at 15,500 × g for 90 min at 4 °C. The supernatant was removed and precipitated protein was resuspended in 50 ml 
of Qβ buffer (10 mM Tris-HCl, 5 mM EDTA, 150 mM NaCl, pH 8.0). Five ml fractions of the resuspended VLPs 
were run on a S500 HR size exclusion column (GE healthcare, UK) equilibrated in Qβ buffer and the fractions 
corresponding to the predicted size of VLPs were collected and pooled from subsequent runs. The pooled VLP-
containing fractions were applied to a CHT type II 80 μm hydroxyapatite (Bio-Rad, UK) column to remove con-
taminating lipopolysaccharide. The column was equilibrated in PBS and the pooled S500 HR elution fractions 
were diluted in PBS until the conductivity was below 12 mS/cm and applied to the column at a flow rate of 1 ml/
min. The column was washed with 10 column volumes of 20 mM Tris pH 7.2 and the VLPs were eluted with 
500 mM Na2HPO4, 1 M NaCl, pH 7.2. The eluate was diluted in PBS until the conductivity was below 12 mS/cm 
and reapplied to the hydroxyapatite column after it had been cleaned with 1 M NaOH for 2 h. This was repeated 
as necessary until the endotoxin content of the elution fraction was below 1 EU per μg.
Pfs25, Pfs25-IMX313-CTag, Pfs25-SpyTag-CTag (GenBank accession number KU302811) and 
SpyCatcher-AP205 (GenBank accession number KU302810) were purified as described previously4, 6. Each 
form of Pfs25 expressed and used in this study comprises the sequence from Alanine-22 to Threonine-193 
with four potential N-linked glycosylation sites (112, 165, 187 and 202) mutated (as described previously)4, 55. 
Briefly: Pfs25-His and Pfs25-IMX313-CTag were expressed in Pichia pastoris under the control of the meth-
anol inducible AOX1 promoter and alpha-mating factor secretion signal sequence allowing inducible expres-
sion and secretion into the culture media. Following expression both proteins were purified from the culture 
supernatant using either a 5 ml HisTrap HP nickel chelate affinity chromatography column (GE Healthcare) for 
Pfs25-His or a 5 ml CaptureSelect™ C-tag affinity matrix column for Pfs25-IMX313-CTag. Pfs25-SpyTag-CTag 
was expressed in HEK293E cells cultured to 2 million cells/mL and transfected with 1 μg plasmid complexed to 
polyethylenimine per million cells. Supernatant was harvested after 72 h and Pfs25-SpyTag-CTag was purified 
using a 5 ml CaptureSelect™ C-tag affinity matrix column. Pfs25-His, Pfs25-IMX313 and Pfs25-SpyTag-CTag 
were further polished by size exclusion chromatography using a HiLoad 16/600 Superdex pg column (GE 
Healthcare). SpyCatcher-AP205 was expressed intracellularly in C41 E. coli using an IPTG inducible promoter. 
VLPs were purified from the bacterial cell lysates using a Ni-NTA agarose resin (Qiagen) and polished by dial-
ysis in a 300 kDa MWCO membrane (SpectrumLabs). Ni-NTA conditions were adjusted such that monomeric 
SpyCatcher-AP205 was washed off the column at a low imidazole concentrations (200 mM) and only intact VLPs 
were retained on the column until elution (2 M imidazole) as previously described6.
Western blots were performed using standard methods4. Briefly, after polyacrylamide gel electrophoresis and 
transfer to blotting membrane, blots were placed in an iBind (Thermo Fisher scientific, UK) apparatus according 
to the manufacturer’s instructions. Primary antibody (polyclonal or monoclonal) and secondary antibody (alka-
line phosphatase conjugated donkey-anti-mouse IgG secondary antibodies [Jackson Immuno Research, USA]) 
probes were diluted to appropriate concentrations in iBind buffer. After washing briefly in deionized water, blots 
were incubated with 1 SIGMAFAST™ BCIP® /NBT tablet (Sigma-Aldrich, UK) dissolved in 10 ml dH2O until 
the desired level of staining was achieved.
Antigen-VLP conjugation. Qβ and Pfs25-His prepared as above were buffer exchanged into PBS by dial-
ysis and concentrated to 2 mg/ml, and 3 mg/ml respectively using a 100 kDa MWCO membrane centrifugal spin 
filter (Millipore). Pfs25-His was incubated with a 5-fold molar excess of N-succinimidyl S-acetylthioacetate 
(SATA) (Pierce, UK) at room temperature for 30 min. The latent sulfhydryls on the SATA-modified protein were 
de-protected with 10 mg/ml Hydroxylamine-HCl (Pierce, UK) for 3 h at room temperature. During this time 
Qβ VLPs were modified with a 10-fold molar excess of Succinimidyl 6-((β-maleimidopropionamido)hexanoate) 
(SMPH) (Pierce, UK) and incubated at room temperature for 2 h. Residual SMPH and SATA were removed 
from both by buffer exchange in a centrifugal spin-filter (Millipore, UK) of the relevant MWCO. The resulting 
thiolated-Pfs25 was mixed with derivatised-Qβ at a molar ratio of 5:1 and incubated at room temperature for 2 h. 
Remaining unconjugated antigen was removed by dialysis against TBS (20 mM Tris, 150 mM NaCl, pH 7.4) three 
times for 3 h using a 100 kDa MWCO membrane.
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Pfs25-SpyTag-CTag and SpyCatcher-AP205 were conjugated as previously described6. Briefly, 
SpyCatcher-VLPs (30 μM) were incubated with 1.5 fold molar excess of Pfs25-SpyTag for 3 h at RT with addition 
of 10 × reaction buffer (40 mM Na2HPO4, 200 mM sodium citrate, pH 6.2). The reaction was then dialyzed with a 
300 kDa cut-off membrane three times against 1,000-fold excess 50 mM glycine, 25 mM sodium citrate, 0.1% (v/v) 
Tween 20, pH 8.0 to remove unreacted Pfs25-SpyTag.
VLP characterisation by size exclusion chromatography. Antigen-conjugated nanoparticles were 
applied to a previously equilibrated Superdex 200 Increase 10/300 GL (GE Healthcare, UK) on an AKTA pure 
fast protein liquid chromatography (FPLC) system (GE Healthcare). The mobile-phase column buffer was 20 mM 
Tris-HCl, 150 M NaCl, pH 7.4 and the applied flow-rate was 0.75 mL/min, all at 21 °C. For calibration, a high 
molecular weight gel filtration standard (GE Healthcare) was used.
Transmission electron microscopy (TEM). 10 μL of VLPs (0.2 mg/mL) were applied to freshly 
glow-discharged carbon 200 mesh copper grids for 2 min, blotted with filter paper, and stained with 2% uranyl 
acetate for 10 s, then blotted and air dried. Grids were imaged in a FEI Tecnai T12 transmission electron micro-
scope at 120 kV using a Gatan US1000 CCD camera.
Vaccinations. All animal experiments and procedures were performed according to the UK Animals 
(Scientific Procedures) Act Project Licence (PPL 30/2414 and 30/2889) and approved by the Oxford University 
Local Ethical Review Body. For all vaccinations, a minimum specification of <1 EU/µg was used as a quality 
control to prevent endotoxin related reactogenicity. Age-matched female BALB/c mice (Harlan, UK), housed 
in specific pathogen-free environments, were vaccinated with 25 μl of vaccine formulation in each leg intramus-
cularly (IM). Protein-in-adjuvant was formulated as follows: 85 μg Alhydrogel (Brenntag) per dose was mixed 
with TBS at room temperature for 15 min, antigen was then added and incubated for a further 45 min at room 
temperature. Dosages were calculated to achieve a final concentration of 1 μg of Pfs25 per dose. Total protein per 
dose for each group is detailed in Table 1. The animals were immunised on days 0 and 21, and blood samples were 
collected on days 20 (three weeks post prime) and 41 (three weeks post boost). The samples were allowed to clot 
at 4 °C overnight before centrifugation at 13,000 × g in a benchtop centrifuge and serum was removed for testing.
Immunofluorescence Assay. Recognition of native parasite Pfs25 antigen by the vaccine-induced anti-
serum was confirmed by immunofluorescence on paraformaldehyde (PFA) fixed ookinetes as described pre-
viously56. Briefly, Pfs25DR3 transgenic Plasmodium berghei (provided by Dr Andrew Blagborough, Imperial 
College, London) ookinete culture smears were fixed for 10 min in 4% PFA/PBS followed by washing in PBS. 
Slides were blocked for 1 h in blocking buffer (3% BSA in PBS) followed by incubation in test antiserum (1:500 
for nanoparticles or 1:100 for monomeric Pfs25) or positive control antibody 4B7 32 (1:500) diluted in 3% BSA in 
PBS for 45 minutes. Alexa-Fluor 488-conjugated goat anti-mouse IgG (Thermo Fisher, UK) (1:800) diluted in 3% 
BSA in PBS was then added and incubated for a further 45 minutes. Slides were then mounted in Mowiol-DAPI 
(Sigma-Aldrich, UK), a cover slip was added and the mounting media was allowed to set overnight at 4 °C in a 
slide box. Unless otherwise stated, all of the above steps were followed by 3 washes for 5 min in PBS and incuba-
tions were performed at room temperature in a humid chamber. Slides were analysed by fluorescence microscopy 
on a DMI3000B microscope (Leica Microsystems, UK).
Pfs25 standardised ELISA. The protocol used to assess anti-Pfs25 antibody titers in serum has been 
described previously4. Briefly, Nunc-Immuno maxisorp plates (Thermo Scientific, UK) were coated with 0.1 μg 
(100 μl of 1 μg/ml stock) P. pastoris expressed Pfs25-His per well in coating buffer (50 mM sodium bicarbonate, 
pH 9.6) and incubated overnight at 4 °C. Plates were washed with PBS + 0.1% Tween-20 (PBS/T) six times and 
blocked for 1 h with 5% skimmed milk in PBS/T at room temperature (RT). Test serum samples were diluted as 
required in PBS/T, before 100 μl of sample were added to triplicate wells and incubated for 2 h at RT. Plates were 
washed as before and 100 μl donkey anti-mouse total IgG conjugated to alkaline phosphatase (Sigma-Aldrich, 
UK) diluted 1:3000 in PBS/T was added to each well and incubated for 1 h at RT. Following a final wash in PBS/T, 
one p-nitrophenylphosphate (Sigma-Aldrich, UK) tablet was dissolved in 1x diethanolamine buffer (Thermo 
Scientific, UK) and 100 μl added to each well as a developing substrate. The optical density (OD) of each well was 
read at 405 nm using an ELx800 absorbance microplate reader (Biotek, UK). A serially diluted standard reference 
serum (as previously reported4) with a known antibody titer was used to determine the antibody titer of indi-
vidual samples. The minimal detection limit (MDL) of the ELISA was 100 AU/ml. Samples which fell below this 
value were defined as having 1 AU/ml in order to display them on a log scale graph.
Antibody Avidity ELISA. Antibody avidity (three weeks post boost) was assessed using a sodium thiocy-
anate (NaSCN)-displacement ELISA. Nunc-Immuno maxisorp plates were coated with recombinant Pfs25-His 
protein over-night, blocked and then washed with PBS/T as described for standardised ELISA. All individual 
serum samples were diluted so that each sample contained the same level of Pfs25 AU (in this study 100 AU). 
Samples were added in duplicate and following incubation and washing, an ascending concentration of the 
NaSCN (0–7 M) was added to the wells. The plates were incubated at RT for 15 min followed by washing and 
further development as in the standardised ELISA.
IgG Purification. To perform standard membrane feeding assays (SMFAs), mouse sera were pooled and the 
IgG purified, as previously described10. Mouse sera from the final bleeds post-immunisation were pooled within 
each test and control group. Equal volumes of serum from all mice in a group were pooled irrespective of indi-
vidual antibody titer. Total IgG was purified using Protein G columns (Pierce, USA) as described previously4 and 
buffer exchanged to 1x PBS.
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Standard Membrane Feeding Assay. The ability of vaccine-induced antibodies to block the development 
of P. falciparum strain NF54 was evaluated by SMFA as previously described13. The percentage of mature Stage 
V gametocytes was adjusted to 0.15% ± 0.05% and the male-female ratio is stable (almost always 1 male: 2–3 
female). Gametocyte cultures were mixed with purified IgG at the concentrations (diluted in PBS) shown in the 
figures and then fed to 4–6 day old starved female Anopheles stephensi (SDA 500) via a parafilm® membrane. The 
mosquitoes were maintained at 26 °C and 80% relative humidity. After 7 days, midguts from twenty mosquitoes 
with eggs per group were dissected, oocysts counted and the number of infected mosquitoes recorded. Percent 
reduction in infection intensity was calculated relative to the respective control IgG tested in the same assay.
Statistical Analysis. Comparison of quantitative data from multiple groups (e.g., antibody titers) was per-
formed using a Kruskal-Wallis test. If significant, a Dunn’s multiple comparison post-test was performed. Avidity 
ELISA data of each sample were fitted to a sigmoidal dose-response (variable slope) curve and the EC50 was 
defined as the concentration of NaSCN required to reduce the OD by 50% between the upper and lower limits.
For SMFA data, 20 mosquitoes per group were analysed and the number of mosquitoes is reflected in the 
95% confidence intervals (CIs) of % inhibition. The best estimate and 95% CIs of % inhibition in oocyst density 
from a single or multiple feeding experiments for each test antibody at each concentration were calculated using 
a negative binomial model with zero inflation model, as described previously13.Oocyst densities of two groups 
were compared using the same model, and Holm corrected p-values were calculated for multiple comparisons.
A linear regression model was used to evaluate difference in functional activity among vaccine groups after 
adjusting other factors4. The log10 transformed ratio of the mean oocyst count in control and test samples was 
the dependent variable, and the square root of anti-Pfs25 AU and vaccine group were independent variables 
in the model. When a test sample showed 100% inhibition, the data point was excluded from the analysis, as it 
was outside of linear range (i.e., log-transformed values became infinity). If the vaccine group effect was signif-
icant, Tukey’s honest significant difference tests were performed to compare different groups. In another linear 
regression analysis, reciprocal of dilution (in a square root scale) from the original pooled serum to the tested 
IgG in a feeder was utilised as one of the independent variables, instead of anti-Pfs25 AU. Since the ratio of 
anti-Pfs25-specific IgG to entire IgG in a sample is considered to be stable before (i.e., in the original pooled 
serum) and after (i.e., in the purified IgG) protein G affinity purification, the anti-Pfs25 AU in the original pooled 
serum and in the purified IgG were used to calculate the dilution factor of each test IgG at each test concentration.
Statistical tests were performed using Prism 6 (GraphPad Software Inc, USA), or JMP11 (SAS Institute Inc, 
USA). P-values < 0.05 were considered significant.
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